Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO)
CUSIP: 019770106
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 344,793,745
- Total 13F shares
- 196,986,783
- Share change
- +8,737,126
- Total reported value
- $288,577,139
- Put/Call ratio
- 38%
- Price per share
- $1.46
- Number of holders
- 167
- Value change
- +$11,150,657
- Number of buys
- 89
- Number of sells
- 70
Quarterly Holders Quick Answers
What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 019770106:
Top shareholders of ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| TPG GP A, LLC |
3/4/5
13F
|
10%+ Owner · Company |
5.4%
from 13F
|
18,716,306
|
$59,413,042 | — | 12 Jan 2022 | |
| FMR LLC |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
23,771,995
|
$50,634,349 | — | 31 Dec 2024 | |
| PFIZER INC |
13F
|
Company |
6.4%
|
22,032,040
|
$46,928,245 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
18,062,655
|
$38,473,455 | — | 31 Dec 2024 | |
| Lynx1 Capital Management LP |
13F
13D/G
|
Company |
5.2%
from 13D/G
|
10,874,723
|
$23,163,160 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.3%
|
8,000,692
|
$17,041,474 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.1%
|
7,249,966
|
$15,442,428 | — | 31 Dec 2024 | |
| Capital World Investors |
13F
|
Company |
2%
|
6,896,552
|
$14,689,656 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.6%
|
5,349,096
|
$11,393,575 | — | 31 Dec 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
1.4%
|
4,927,340
|
$10,495,234 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.3%
|
4,485,572
|
$9,555,000 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
1.3%
|
4,360,232
|
$9,287,294 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.1%
|
3,736,132
|
$7,957,962 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1%
|
3,561,626
|
$7,585,928 | — | 31 Dec 2024 | |
| Foresite Capital Management VI LLC |
13F
|
Company |
1%
|
3,448,275
|
$7,344,826 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.94%
|
3,232,618
|
$6,886,971 | — | 31 Dec 2024 | |
| Eric Thomas Schmidt |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
2,447,772
mixed-class rows
|
$6,396,524 | — | 22 Mar 2023 | |
| Wildcat Capital Management, LLC |
13F
|
Company |
0.85%
|
2,920,787
|
$6,221,276 | — | 31 Dec 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.83%
|
2,867,750
|
$6,108,308 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.79%
|
2,712,139
|
$5,776,856 | — | 31 Dec 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.78%
|
2,702,200
|
$5,755,686 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.61%
|
2,106,577
|
$4,487,009 | — | 31 Dec 2024 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
0.52%
|
1,798,163
|
$3,830,087 | — | 31 Dec 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.44%
|
1,500,000
|
$3,195,000 | — | 31 Dec 2024 | |
| Patient Square Capital LP |
13F
|
Company |
0.43%
|
1,489,909
|
$3,173,506 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.38%
|
1,305,232
|
$2,780,143 | — | 31 Dec 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.36%
|
1,240,118
|
$2,641,451 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.34%
|
1,188,838
|
$2,532,225 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.34%
|
1,163,743
|
$2,478,772 | — | 31 Dec 2024 | |
| GILEAD SCIENCES, INC. |
13F
|
Company |
0.34%
|
1,156,689
|
$2,463,748 | — | 31 Dec 2024 | |
| Alison Moore |
3/4/5
|
Chief Technical Officer |
—
mixed-class rows
|
1,105,469
mixed-class rows
|
$2,135,517 | — | 22 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.29%
|
998,596
|
$2,127,010 | — | 31 Dec 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.25%
|
849,658
|
$1,809,772 | — | 31 Dec 2024 | |
| Veer Bhavnagri |
3/4/5
|
General Counsel |
—
class O/S missing
|
556,049
|
$1,765,122 | — | 14 Mar 2023 | |
| Rafael Amado |
3/4/5
|
EVP of R&D |
—
class O/S missing
|
541,946
|
$1,720,353 | — | 07 Oct 2022 | |
| UBS Group AG |
13F
|
Company |
0.23%
|
796,491
|
$1,696,524 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.22%
|
761,286
|
$1,621,538 | — | 31 Dec 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.21%
|
716,236
|
$1,525,583 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.16%
|
554,541
|
$1,181,172 | — | 31 Dec 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.16%
|
545,388
|
$1,161,676 | — | 31 Dec 2024 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.14%
|
484,715
|
$1,032,443 | — | 31 Dec 2024 | |
| ZACKS INVESTMENT MANAGEMENT |
13F
|
Company |
0.14%
|
480,874
|
$1,024,261 | — | 31 Dec 2024 | |
| NORDEA INVESTMENT MANAGEMENT AB |
13F
|
Company |
0.13%
|
460,641
|
$985,772 | — | 31 Dec 2024 | |
| Raiffeisen Bank International AG |
13F
|
Company |
0.12%
|
430,000
|
$903,000 | — | 31 Dec 2024 | |
| Cerity Partners LLC |
13F
|
Company |
0.11%
|
387,387
|
$831,567 | — | 31 Dec 2024 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.11%
|
376,661
|
$802,288 | — | 31 Dec 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.11%
|
367,445
|
$782,658 | — | 31 Dec 2024 | |
| Aberdeen Group plc |
13F
|
Company |
0.11%
|
364,382
|
$776,134 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.1%
|
330,769
|
$704,539 | — | 31 Dec 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.09%
|
305,895
|
$651,120 | — | 31 Dec 2024 |
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) as of Q1 2025
As of 31 Mar 2025,
Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) was held by
167 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
196,986,783 shares.
The largest 10 holders included
Pfizer Inc, TPG GP A, LLC, BlackRock, Inc., Capital World Investors, Lynx1 Capital Management LP, Darwin Global Management, Ltd., CITADEL ADVISORS LLC, VANGUARD GROUP INC, FMR LLC, and GOLDMAN SACHS GROUP INC.
This page lists
168
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
170
Q1 2025 holders
167
Holder diff
-3
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.